/ 62	
<i>.</i> 61.	An isolated polypeptide that is 90% identical to the amino acid D NO:299, wherein said polypeptide is expressed in breast tumor
goguenos of CEO I	D NO 200 11
sequence of SEQ I	D NO:299, wherein said polypeptide is expressed in breast tumor
tissue.	
63	62
<b>62</b> .	An isolated polypeptide according to claim \$1, wherein said
	dentical to the amino acid sequence of SEQ ID NO:299.
,	<b>\</b>
64	
<sup>1</sup> 63.	An isolated polypeptide comprising the amino acid sequence
encoded by the polynucleotide sequence of SEQ ID NO:292.	
∫ 65 64.	
64.	An isolated polypeptide comprising the amino acid sequence of
SEQ ID NO:299.	
,/	
66.	61
. 1	An isolated polypeptide according to claim 60, in combination
with a physiologicall	y acceptable carrier.
67	\ 61
67 66.	An isolated polypeptide according to claim 60, in combination
with an immunostime	<b>,</b>
with an initialiostilli	nant.
68	\ 61
61.	An isolated polypeptide according to claim 66, wherein said

69
68. An isolated polypeptide according to claim 66, wherein said immunostimulant induces a predominantly Type I response.

immunostimulant is an adjuvant.

## **REMARKS**

Favorable consideration of the above identified patent application is respectfully requested in view of the above amendments and following remarks.